QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Developm...
QurAlis reported ANQUR trial data showing target engagement and signals on disease progression for QRL-201, a first-in-class precision medicine for sporadic ALS.
Why it mattersANQUR's target-engagement and disease-progression signals for QRL-201 in sporadic ALS justify prioritizing follow-on investment decisions.